SitemapContact Us
닫기
Search
Advanced Search +
닫기
Quick links
Most Cited Most Read Ahead of Print Archives Go to E-submission

Letter to the Editor

Split Viewer

Blood Res 2016; 51(1):

Published online March 31, 2016

https://doi.org/10.5045/br.2016.51.1.58

© The Korean Society of Hematology

Comparison of an international scale method and a log reduction method for monitoring of early molecular response in chronic myeloid leukemia patients

Sunhyun Ahn1, Young Ae Lim1, Wee Gyo Lee1, Seong Hyun Jeong2, Joon Seong Park2, and Sung Ran Cho1*

Author Info. +

1Department of Laboratory Medicine, Ajou University School of Medicine, Suwon, Korea.

2Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.

Correspondence to : Sung Ran Cho. Department of Laboratory Medicine, Ajou University School of Medicine, 164 World cup-ro, Youngtong-gu, Suwon 16499, Korea. sungran@ajou.ac.kr

Received: March 6, 2015; Revised: April 14, 2015; Accepted: May 7, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

FIGURES

Go to
Fig. 1.

Correlation between the international scale (IS) values and the log10 reductions in BCR-ABL1 levels in the chronic myeloid leukemia patients at 3 months after imatinib mesylate therapy. Abscissa indicates IS values obtained by the BCR-ABL Mbcr IS-MMR Dx kit. Ordinate indicates the log10 reductions in BCR-ABL1 levels from baseline obtained by the LightCycler t(9;22) quantification kit.


TABLES

Go to
Table. 1.

Table 1 Clinical and laboratory findings of the patients showing a discrepancy between the log reduction method and the IS method.

a)≥1 log10 reduction at 3 months was considered as EMR.

b)≤10% IS at 3 months was considered as EMR.

Abbreviations: CML-CP, chronic myeloid leukemia in chronic phase; EMR, early molecular response; IS, international scale.

REFERENCES

Go to
  1. Hughes, TP, Kaeda, J, Branford, S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med, 2003;349;1423-1432.
    Pubmed
  2. Branford, S, Fletcher, L, Cross, NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 2008;112;3330-3338.
    Pubmed
  3. Hughes, T, Deininger, M, Hochhaus, A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006;108;28-37.
    Pubmed
  4. Baccarani, M, Cortes, J, Pane, F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol, 2009;27;6041-6051.
    Pubmed
  5. Marin, D, Ibrahim, AR, Lucas, C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol, 2012;30;232-238.
    Pubmed
  6. Hanfstein, B, Müller, MC, Hehlmann, R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 2012;26;2096-2102.
    Pubmed
  7. Park, JS, Yi, JW, Jeong, SH, et al. Comparison of multiplex reverse transcription polymerase chain reaction and conventional cytogenetics as a diagnostic strategy for acute leukemia. Int J Lab Hematol, 2008;30;513-518.
    Pubmed
  8. Gabert, J, Beillard, E, van der Velden, VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 2003;17;2318-2357.
    Pubmed
  9. Beillard, E, Pallisgaard, N, van, der, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia, 2003;17;2474-2486.
    Pubmed
  10. Quintás-Cardama, A, Kantarjian, H, Jones, D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood, 2009;113;6315-6321.
    Pubmed
  11. Qin, YZ, Jiang, Q, Jiang, H, et al. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?. Leuk Res, 2013;37;1035-1040.
    Pubmed
  12. Druker, BJ, Guilhot, F, O'Brien, SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006;355;2408-2417.
    Pubmed
  13. Fava, C, Kantarjian, H, Cortes, J. Molecular resistance: an early indicator for treatment change?. Clin Lymphoma Myeloma Leuk, 2012;12;79-87.
    Pubmed
  14. Stanoszek, LM, Crawford, EL, Blomquist, TM, Warns, JA, Willey, PF, Willey, JC. Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples. J Mol Diagn, 2013;15;391-400.
    Pubmed
  15. Cross, NC, White, HE, Müller, MC, Saglio, G, Hochhaus, A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia, 2012;26;2172-2175.
    Pubmed

Article

Letter to the Editor

Blood Res 2016; 51(1): 58-61

Published online March 31, 2016 https://doi.org/10.5045/br.2016.51.1.58

Copyright © The Korean Society of Hematology.

Comparison of an international scale method and a log reduction method for monitoring of early molecular response in chronic myeloid leukemia patients

Sunhyun Ahn1, Young Ae Lim1, Wee Gyo Lee1, Seong Hyun Jeong2, Joon Seong Park2, and Sung Ran Cho1*

1Department of Laboratory Medicine, Ajou University School of Medicine, Suwon, Korea.

2Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.

Correspondence to: Sung Ran Cho. Department of Laboratory Medicine, Ajou University School of Medicine, 164 World cup-ro, Youngtong-gu, Suwon 16499, Korea. sungran@ajou.ac.kr

Received: March 6, 2015; Revised: April 14, 2015; Accepted: May 7, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Fig 1.

    Download
    Figure 1.

    Correlation between the international scale (IS) values and the log10 reductions in BCR-ABL1 levels in the chronic myeloid leukemia patients at 3 months after imatinib mesylate therapy. Abscissa indicates IS values obtained by the BCR-ABL Mbcr IS-MMR Dx kit. Ordinate indicates the log10 reductions in BCR-ABL1 levels from baseline obtained by the LightCycler t(9;22) quantification kit.

    Blood Research 2016; 51: 58-61https://doi.org/10.5045/br.2016.51.1.58

    Table 1 . Clinical and laboratory findings of the patients showing a discrepancy between the log reduction method and the IS method..

    a)≥1 log10 reduction at 3 months was considered as EMR..

    b)≤10% IS at 3 months was considered as EMR..

    Abbreviations: CML-CP, chronic myeloid leukemia in chronic phase; EMR, early molecular response; IS, international scale..

    References

    1. Hughes, TP, Kaeda, J, Branford, S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med, 2003;349;1423-1432.
      Pubmed
    2. Branford, S, Fletcher, L, Cross, NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 2008;112;3330-3338.
      Pubmed
    3. Hughes, T, Deininger, M, Hochhaus, A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006;108;28-37.
      Pubmed
    4. Baccarani, M, Cortes, J, Pane, F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol, 2009;27;6041-6051.
      Pubmed
    5. Marin, D, Ibrahim, AR, Lucas, C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol, 2012;30;232-238.
      Pubmed
    6. Hanfstein, B, Müller, MC, Hehlmann, R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 2012;26;2096-2102.
      Pubmed
    7. Park, JS, Yi, JW, Jeong, SH, et al. Comparison of multiplex reverse transcription polymerase chain reaction and conventional cytogenetics as a diagnostic strategy for acute leukemia. Int J Lab Hematol, 2008;30;513-518.
      Pubmed
    8. Gabert, J, Beillard, E, van der Velden, VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 2003;17;2318-2357.
      Pubmed
    9. Beillard, E, Pallisgaard, N, van, der, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia, 2003;17;2474-2486.
      Pubmed
    10. Quintás-Cardama, A, Kantarjian, H, Jones, D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood, 2009;113;6315-6321.
      Pubmed
    11. Qin, YZ, Jiang, Q, Jiang, H, et al. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?. Leuk Res, 2013;37;1035-1040.
      Pubmed
    12. Druker, BJ, Guilhot, F, O'Brien, SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006;355;2408-2417.
      Pubmed
    13. Fava, C, Kantarjian, H, Cortes, J. Molecular resistance: an early indicator for treatment change?. Clin Lymphoma Myeloma Leuk, 2012;12;79-87.
      Pubmed
    14. Stanoszek, LM, Crawford, EL, Blomquist, TM, Warns, JA, Willey, PF, Willey, JC. Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples. J Mol Diagn, 2013;15;391-400.
      Pubmed
    15. Cross, NC, White, HE, Müller, MC, Saglio, G, Hochhaus, A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia, 2012;26;2172-2175.
      Pubmed
    Blood Res
    Volume 59 2024
    Current Issue Archives

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download